

Gene Therapies for Hemophilia A – Prior Authorization Request Form for Roctavian® (Valoctocogene roxaparvovec-rvox), #166

Medical Policy #168 Gene Therapies for Hemophilia A or B

CLINICAL DOCUMENTATION

- Clinical documentation that supports the medical necessity criteria for Roctavian must be submitted.
- If the patient does not meet all the criteria listed below, please submit a letter of medical necessity with a request for Clinical Exception (Individual Consideration) explaining why an exception is justified.

Requesting Prior Authorization Using Authorization Manager

Providers will need to use <u>Authorization Manager</u> to submit initial authorization requests for services. Authorization Manager, available 24/7, is the quickest way to review authorization requirements, request authorizations, submit clinical documentation, check existing case status, and view/print the decision letter. For commercial members, the requests must meet medical policy guidelines.

To ensure the request is processed accurately and quickly:

- Enter the facility's NPI or provider ID for where services are being performed.
- Enter the appropriate surgeon's NPI or provider ID as the servicing provider, *not* the billing group.

Authorization Manager Resources

Detient Information

Congenital Hemophilia A

• Refer to our Authorization Manager page for tips, guides, and video demonstrations.

For out of network providers: Requests should still be faxed to 888-973-0726.

Please check off that the patient meets <u>ALL</u> the following criteria:

Patient Name:	Today's Date:
BCBSMA ID#:	Date of Treatment:
Date of Birth:	Place of Service: Outpatient ☐ Inpatient ☐
	Distributor:
Physician Information	Facility Information
Name:	Name:
Address:	Address:
Phone #:	Phone #:
Fax#:	Fax#:
NPI#:	NPI#:
Please check off if the patient has the following diagnosi	s:

1.	Individual is 18 years of age or older; AND	
2.	Assigned male at birth; AND	
3.	Diagnosis of severe or moderately severe hemophilia A as defined by residual Factor VIII (FVIII) levels ≤ 1 IU/dL; AND	
4.	Currently receiving FVIII prophylaxis; AND	
5.	No history of FVIII inhibitors or a positive screen results of ≥ 0.6 BU using the Nijmegen-Bethesda assay; AND	
6.	No detectable pre-existing antibodies to the adeno-associated virus serotype 5 (AAV5) capsid; AND	
7.	No history of receiving gene therapy or under consideration for treatment for another gene therapy for hemophilia A; AND	
8.	Medications is being prescribed by or in consultation with a hematologist or a prescriber who specializes in hemophilia A; AND	
9.	A baseline liver health assessment including but not limited to ALT; AND	
10.	Educated regarding alcohol abstinence and concomitant use of certain medications (e.g., isotretinoin, efavirenz); AND	
11.	HIV negative; AND	
12.	No active hepatitis B and/or hepatitis C infection.	
HC Co	PCS Code Description des	
C93	0 0	
J34	Q	
J35	90 Unclassified biologics	
	riders should enter the <u>relevant diagnosis code(s)</u> below:	
Co	de Description	

Providers should enter other relevant code(s) below:

Code Description